Fecal transfer gains ground in chronic diarrhea care: full analysis

Version 2 — Full analysis

Fecal transfer for chronic diarrhea is no longer just a conference-curiosity topic in veterinary medicine. Newer canine data and the first formal companion-animal clinical guidelines suggest fecal microbiota transplantation, or FMT, is becoming a more structured adjunct option for chronic enteropathy, even as the evidence base remains early and uneven. A 2025 Journal of Veterinary Internal Medicine paper reported meaningful short-term clinical improvement in dogs with chronic inflammatory enteropathy after rectal FMT, adding momentum to a treatment approach that has mostly lived in case reports, small cohorts, and specialist practice. At the same time, case-based veterinary media discussions are starting to present FMT less as a novelty and more as a practical option clinicians may want in their chronic-diarrhea toolbox. (academic.oup.com)

The backdrop is a broader rethinking of dysbiosis, chronic diarrhea management, and antibiotic stewardship in small-animal medicine. In its 2024 clinical guidelines, the Companion Animal FMT Consortium said FMT is now recommended in veterinary medicine as an adjunctive microbial-directed therapy for canine parvoviral enteritis, canine acute diarrhea, and chronic enteropathy in both dogs and cats. The same document emphasized that the field is still in its infancy, but argued that donor programs and treatment workflows are feasible across practice types, not just referral centers. That practical framing also showed up in a Dr. Andy Roark podcast episode featuring veterinarian Dr. Lily Chin, which focused on how fecal transfer might be approached in real-world chronic diarrhea cases and reflected growing interest from clinicians who have not yet used the technique themselves. (pure.ed.ac.uk)

The 2025 JVIM study was small, involving seven dogs with chronic enteropathy that received fecal transfer from two healthy donor dogs. Six dogs received a single FMT, and one dog received three FMTs after relapses. Median CCECAI scores fell from 8 before treatment to 3 within one week and to 1 by day 30, with an average response duration of about 10 weeks. Still, the microbiome findings were more complicated than the clinical response: investigators did not observe consistent changes in recipient microbiota composition or diversity over time, despite symptom improvement. That leaves open a central question for clinicians and researchers alike: whether FMT’s benefit is being mediated through mechanisms not captured well by current sequencing approaches, or whether patient selection and dosing remain too variable. (academic.oup.com)

The guidelines help explain why interest is growing despite those unanswered questions. They describe FMT as generally safe, well-tolerated, and minimally invasive, and they include practical recommendations for donor selection, infectious disease screening, preparation, and administration. They also discourage pre-FMT antimicrobial use unless otherwise clinically indicated, explicitly tying FMT protocols to antimicrobial stewardship. For chronic enteropathy, the consortium notes that repeated treatments can be beneficial in dogs, citing earlier retrospective data in 41 dogs where a median of three enemas was used and many responders improved further after a second treatment. (pure.ed.ac.uk)

There are also clear cautions. The same guideline says evidence for cats is low, with feline use in acute or chronic enteropathy still based largely on anecdotal reports rather than controlled studies. It also notes that while FMT is generally considered safe, reported adverse effects in companion animals can include worsening diarrhea, bloating, flatulence, abdominal pain, nausea, vomiting, reduced appetite, and, more rarely, fever or dehydration. That means practices considering fecal transfer need protocols, informed consent, and donor-screening discipline, not just enthusiasm for a microbiome-based therapy. (pure.ed.ac.uk)

The conversation is also expanding in everyday veterinary education. In the “Cone of Shame” episode on fecal transfer for chronic diarrhea, Dr. Andy Roark described growing personal interest in microbiome therapy and positioned the discussion around a common clinical scenario: a chronic diarrhea case that is not improving. Guest Dr. Lily Chin, a practice owner who uses these approaches in practice, walked through how she thinks about such cases and what fecal transplant might look like in a real clinic setting. That kind of case-based framing matters because it suggests the topic is moving beyond abstract microbiome enthusiasm and into practical clinician decision-making. (drandyroark.com)

Why it matters: For veterinarians, the real significance is less about a single study and more about maturation of the category. Chronic diarrhea and chronic enteropathy cases are often frustrating for clinicians and pet parents, especially when diet trials, symptomatic care, or immunomodulation don’t produce stable control. FMT is starting to look like a legitimate adjunct in select cases, with the added appeal of fitting a stewardship-minded approach that may reduce reflexive antimicrobial use. It is also increasingly being discussed as a usable option by practicing veterinarians, not just researchers or referral specialists. But it’s not yet a plug-and-play standard of care. The best-supported evidence is still in dogs, treatment durability appears variable, and there’s still no settled answer on ideal route, dose, frequency, or how to measure successful engraftment. (academic.oup.com)

The conversation is also expanding beyond chronic diarrhea. In a September 17, 2025 episode summary on Dr. Andy Roark’s site, emergency veterinarian Dr. James Oldeschulte framed fecal transplants as increasingly relevant not only for chronic diarrhea and parvo, but also for acute diarrhea, with capsule-based delivery and easier access potentially broadening uptake. That reflects where industry discussion seems to be heading: from “does this work at all?” toward “which patients, which protocols, and in what setting?” (drandyroark.com)

What to watch: The next phase will likely center on larger randomized trials, repeat-treatment schedules, donor-bank standardization, and stronger feline data. A randomized controlled trial published in April 2026 on FMT as adjunctive treatment in dogs with chronic enteropathy suggests that more rigorous prospective evidence is now arriving, which could help move the field from promising but variable practice to clearer clinical pathways. Just as important, expect more hands-on guidance for general practitioners as educational content increasingly translates microbiome therapy from specialist concept to day-to-day case management. (pubmed.ncbi.nlm.nih.gov)